Ketamine Articles Archives

IV Ketamine Could Get Its First FDA Psychiatric Indication. Here Is What Would Actually Change

Last reviewed and updated: August 13, 2026. Headlines about the FDA and ketamine will multiply this year. Most operators will read them wrong. Some describe a generic manufacturing application. One concerns NRX-100, a specific IV ketamine product pursuing a psychiatric indication. That program could change how clinics approach coverage, marketing and protocols. Knowing which is […]

England Has a Recreational Ketamine Crisis. Here Is How American Clinics Keep It From Happening Here

In one Manchester treatment cohort, 64 percent of the people being treated for ketamine problems were under 18. Forty two percent were between 13 and 16. That is what a recreational ketamine crisis looks like once it has fully arrived, and England is living in one. America is not, and the reason has less to […]

Psilocybin Sessions for PTSD Are Mostly Silent. The Argument About What to Call Them Is Not

A new analysis found psilocybin dosing sessions for PTSD are silent 78 percent of the time. Why the authors want the name changed, and who benefits if it is.

Ketamine Raised Morning Cortisol in a New Trial. Here Is What That Might Mean

A randomized trial found higher morning cortisol 24 hours after ketamine. Bigger rises tracked with less suicidal thinking, though more data needed.

Cluster Headaches Have New Trial Data. Ketamine Clinics Should Be Paying Attention

Two 2024 randomized trials cut cluster headache attacks with pulse dose psilocybin. Where ketamine sits, why these patients overlap with yours, and the access gap.

Ketamine Patients and GLP-1 Patients Are Often the Same People

47 percent of peptide clinics now offer a GLP-1. Depression, drinking and metabolic disease cluster in the same patients.

Psychedelic Trials Are Going Intravenous. Ketamine Clinics Already Have That Room

A new trial of intravenous psilocin points to where psychedelic delivery is heading. Ketamine clinics already have the infusion rooms and titration skills it needs.

Three Psychedelic Companies Analysts Say Could Be Acquired Next

The Deal That Changed the Temperature Eli Lilly agreed in July to pay up to $3.8 billion for AtaiBeckley. That number reset expectations across psychedelic medicine. Analysts now openly discuss which company gets bought next. For clinic owners, the question matters more than it might appear. The companies being courted are building the treatments your […]

New Research Links Your Immune System to Depression Relief

Researchers found that these therapies change how the immune system talks to the brain. The work appeared in the journal Molecular Psychiatry.

Before a Buyer Calls: Getting Your Ketamine Clinic Ready for Acquisition

The first call rarely announces itself as an offer. It sounds like a compliment, someone building a platform in your region admires what you have built and wonders whether you have ever thought about partners. What happens next depends almost entirely on work you either did or did not do during the two years before […]